论文部分内容阅读
作者研究小剂量肝素对首次心肌梗塞(MI)患者预防再梗塞的效果。研究对象为728例首次 Q 波型心肌梗塞,年龄50～75岁;收入研究前6～18个月曾发生一次经确诊的 MI。肝素剂量为每日皮下注射肝素钙(calciparina)12 500IU。728例中,肝素组363(男326,女37)例,平均年龄60.5±7.0岁;对照组365(男320,女45)例,平均年龄60.9±7.0岁。两组患者基本情况相似,但对照组舒张压较高(P=0.022),口服抗血小板药者稍多(P=0.02)。肝素组平均随访708±265天,对照组687±251天;失访者各占7.7％(28/363例)和6.3％(23/365例)。随访期肝素组停药者60例(16.5％),但仅23例(6.3％)因副作用而停药。
The authors studied the effect of low-dose heparin on preventing reinfarction in first-episode myocardial infarction (MI). The study population was 728 first-episode Q-wave myocardial infarctions, aged 50-75 years; a confirmed MI occurred 6-8 months prior to the income study. The dose of heparin is daily subcutaneous injection of 12500 IU of calciparina. In 728 cases, the average age was 60.5 ± 7.0 years in 363 (male 326, female 37) patients in the heparin group and 365 (male 320, female 45) in the control group, with an average age of 60.9 ± 7.0 years. The basic conditions were similar between the two groups, but diastolic blood pressure was higher in the control group (P = 0.022) and slightly more in the oral antiplatelet group (P = 0.02). The average follow-up of heparin group was 708 ± 265 days, while that of control group was 687 ± 251 days. The proportion of those who lost their interviews was 7.7% (28/363 cases) and 6.3% (23/365 cases) respectively. Sixty patients (16.5%) in the heparin group were discontinued during the follow-up period, but only 23 patients (6.3%) discontinued due to side effects.